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Abstract: One of the main challenges in drug development is the prediction of in vivo 
toxicity based on in vitro data. The standard cultivation system for primary human 
hepatocytes is based on monolayer cultures, even if it is known that these conditions result in 
a loss of hepatocyte morphology and of liver-specific functions, such as drug-metabolizing 
enzymes and transporters. As it has been demonstrated that hepatocytes embedded between 
two sheets of collagen maintain their function, various hydrogels and scaffolds for the 3D 
cultivation of hepatocytes have been developed. To further improve or maintain hepatic 
functions, 3D cultivation has been combined with perfusion. In this manuscript, we discuss 
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the benefits and drawbacks of different 3D microfluidic devices. For most systems that are 
currently available, the main issues are the requirement of large cell numbers, the low 
throughput, and expensive equipment, which render these devices unattractive for research 
and the drug-developing industry. A higher acceptance of these devices could be achieved 
by their simplification and their compatibility with high-throughput, as both aspects are of 
major importance for a user-friendly device. 
Keywords: primary human hepatocytes; three-dimensional (3D) cell culture;  
two-dimensional (2D) cell culture; in vitro model; hydrogels; scaffolds; drug-induced 
hepatotoxicity; long-term culture 
 
1. Introduction 
One of the main challenges in drug development and safety assessments is the prediction of in vivo 
drug-induced hepatotoxicity based on in vitro data. The number of laboratory animals in preclinical 
stages could be significantly reduced by cultivation systems that have been validated and approved by 
regulatory authorities. Nowadays the gold standard consinsts of primary human hepatocytes (pHH) in 
conventional monolayer cultures (2D), as hepatic functions and drug-metabolizing enzymes in freshly 
isolated hepatocytes are close to the in vivo situation [1,2]. However, the detection of metabolism-mediated 
hepatotoxicity of drugs fails in vitro [1–3], as hepatocytes rapidly lose their morphology [4,5] and their 
liver specific functions, such as detoxification, activity of phase I and phase II enzymes, and the 
production of plasma proteins like albumin [6–8] under these conditions. In patients, metabolism-mediated 
hepatotoxicity can lead to drug-induced liver injury (DILI), a severe clinical event associated with 
acute liver disease and liver failure [9,10]. Furthermore DILI is the main reason for post-market 
retraction and issuance of warnings of approved drugs as well as drug failure during clinical trials [11]. 
In a recent European retrospective study the incidence of DILI has been estimated to be ~19 new cases 
per 100,000 persons each year [12]. The poor predictability of DILI from preclinical animal experiments 
is based on species-specific differences in drug metabolism between experimental species and humans 
[13,14]. Therefore detection of hepatotoxicity before drugs are tested in animals and clinical trials is an 
important issue in order to minimize the occurrence of DILI. Consequently, there is a demand in the 
pharmaceutical industry for improved hepatocyte-based screening models reflecting human in vivo toxicity. 
In this short review, we compare existing cultivation techniques for hepatocytes. We specifically 
focus on the latest advances in the cultivation of hepatocytes in a 3D environment and their application 
in preclinical drug development, including our own attempts to develop a microfluidic device. 
2. 2D Cultivation Models for Hepatocytes 
The advantages and drawbacks of hepatocytes cultured in different conditions are summarized in 
Table 1. The gold standard consists of primary human hepatocytes cultivated under monolayer 
conditions, as it has been demonstrated that the extrapolation of hepatotoxic data from other 
experimental species to humans is difficult due to interspecies differences [13,14].  
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Table 1. Advantages and drawbacks of cultivation systems for hepatocytes. 
Cultivation Advantages Disadvantages Reference 
2D    
Monolayer Gold standard for drug metabolism and toxicity Rapid loss of morphology and cell polarity [8,9,15] 
 Ideal for testing interindividual and interspecies 
differences in metabolism  
Rapid loss of drug metabolizing capability, decrease of 
albumin production and cell-cell interaction) 
 
 Maintenance of key functions as carbohydrate metabolism 
and plasma protein synthesis (24–72 h) 
Limited availability  
Co-culture Improved functionality of all cell types No real standard established [8,16–19] 
 Increased expression of phase I and  
phase II enzymes 
High variability between different laboratories  
 Maintenance of cell morphology   
 Inducibility of CYPs   
3D    
Hydrogels, scaffolds 
scaffold-free 
Long-term maintenance of liver-specific functions Lack of established standards [8,9,15,20–25] 
 Increased sensitivity towards drugs Not adjusted to high throughput  
 Long-term expression of phase I and  
phase II enzymes 
Cell recovery for further analysis is difficult  
Co-culture with  
liver-drived cell types 
Improved expression of phase I and phase II enzymes, 
Including inducibility by drugs 
No real standard established 
[17,26,27] Not adjusted to high throughput, high variability regarding 
cell viability and differentiation 
 Maintenance of cell polarity, cell-cell contacts and bile 
canaliculi 
  
 Mimicks in vitro architecture   
 Longer cell viability    
Microfluidic devices 
Sustained liver like cell functionality and increased liver 
specific functions 
No standardized system available so far 
[8,9,15] 
Not adjusted to high throughput 
 Precisely adjusted flow/drug concentrations   
 Enable microscopic examination   
 Formation of a sinusoid-like shape (HepaChip®)   
 Fast differentiation of the cells after flow induction   
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As there exists an immense demand in the pharmaceutical industry for human hepatocytes for 
toxicological testing and as the existing cultivation techniques do not sufficiently mimic the in vivo 
situation, an improvement and standardization of the existing cultivation techniques are urgently required. 
2.1. Heptocyte Monolayer Cultivation 
Most systems for the cultivation of hepatocytes are 2D monolayer cultures, which are based on the 
coating of surfaces with extracellular matrices (ECM) such as collagen. Under these conditions, human 
hepatocytes maintain key specific functions such as carbohydrate metabolism, plasma protein 
synthesis and CYP expression for a few days [8,11,15,28]. The cultivation of hepatocytes under 
monolayer conditions has been extensively used for drug-testing, as well as for investigating protective 
drug effects and underlying mechanisms of drug toxicity [14,29,30]. Unfortunately, under these conditions, 
hepatocytes de-differentiate and lose their biotransformation capacity within a few days [28], 
conferring human hepatocytes a very limited time-frame for toxicological studies [8,9,29]. 
2.2. Co-Cultivation of Hepatocytes 
One main obstacle of hepatocytes monolayer cultures in 2D is the lack of cell-cell interaction 
between individual hepatocytes and their limited ability to reproduce hepatotoxic effects in vitro [16]. 
Furthermore, current techniques for hepatocyte cultivation lack cell-cell communication between different 
cell types [8,16]. Co-culture of hepatocytes with different cell types such as human adipose-derived stem 
cells [17,27], human umbilical vein endothelial cells [26], fibroblasts [19], and different non-parenchymal 
liver cells [8,16] maintain cell functionality of all cell types and the biotransformation capacity of 
hepatocytes. However, these co-cultivation methods have a high lab-to-lab variability and do not match 
the requirements of the pharmaceutical industry, as they are not adjusted to high throughput so far. 
2.3. 3D Cultivation Systems for Hepatocytes 
In the human body, each tissue has a defined stiffness, and the cells are embedded in a  
three-dimensional environment which is not reflected under 2D cultivation conditions [31,32]. 
Although, for a long time, monolayer cultures have been a cost-effective and practical method to 
propel the investigation of hepatotoxicity, there exists an urgent demand for the development of systems 
which enable 3D cultivation of hepatocytes, which are in addition suitable for routine applications and 
high throughput screenings for drug development. An indispensable prerequisite for three-dimensional 
matrices is permeability to support metabolic activities, transport of large macromolecules and to 
enable cell-cell interactions [33]. As the maintenance of hepatocyte function and the delay of 
de-differentiation are especially important during drug screening processes, several cultivation 
systems, which allow the assembly into three-dimensional (3D) structures, have been developed in 
recent years by using either extracellular matrix (ECM) proteins or synthetic scaffolds (reviewed in [34]). 
The advantages and drawbacks of 3D hepatic cell cultures are summarized in Table 1. 
The interaction of hepatocytes with a three-dimensional environment preserves their function as 
well as the expression of specific transporters, cell-cell communication via tight and gap junctions, and 
the formation of bile canaliculi [8,35]. Although some of the commercially available 3D cultivation 
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systems have already delivered promising data [36–38], the exclusion of a continuous flow which is 
known to facilitate active transport of nutrients, metabolites, and oxygen, is a major drawback [39,40]. 
However, the combination of 3D cultivation with a continuous flow often leads to complex systems 
with restricted throughput and the requirement of high cell numbers, which is in contrast to the limited 
availability of primary human hepatocytes. To overcome these restrictions, recent attempts have led to 
the development of miniaturized 3D flow culture systems in order to reduce the amount of required 
cells and to enable high throughput applications, as these features would facilitate acute and dose 
repeated hepatotoxicity screenings. 
One of the most important aspects driving the investigation of matrices for the 3D cultivation of 
hepatocytes is the preservation of function, in particular of the activity of drug-metabolizing enzymes 
and of hepatic transporters, over several days (acute model) or even up to 4 weeks (chronic hepatotoxicity). 
Currently available systems can be classified into the three following categories (i) hydrogels, 
(ii) microporous scaffolds, and (iii) scaffold-free 3D formats, such as spheroids or cell aggregates. 
2.3.1. Hydrogels 
Hydrogels present water-swollen polymers derived from natural or synthetic resources (Table 2). 
Naturally-derived hydrogels, such as collagen and Matrigel®, are composed of extracellular matrix and 
other proteins. Collagen can be easily extracted from rat tail tendons and used for the cultivation of 
cells between two layers of collagen (collagen-sandwich) [5], resembling the in vivo phenotype such as 
the polygonal shape, restoration of cell-cell contacts, formation of bile canaliculi and maintenance of 
liver-specific functions (CYP activities, albumin, and urea synthesis) [2]. Moreover, Matrigel® is a 
mixture of matrix proteins secreted by Engelbreth-Holm-Swarm sarcoma cells, which seem to be superior 
to collagen, as overlayed hepatocytes exhibit an improved bile canalicular network formation [38] and 
preserved liver-specific functions [2]. 
However, although naturally derived 3D cultivation systems dispose of a high biocompatibility, the 
remaining obstacles are high batch-to-batch variations, impeding the reproducibility of experimental 
results, and poor mass transfer of nutrients and oxygen. In order to overcome these disadvantages, 
synthetically derived hydrogels have been developed. One of the most extensively used synthetic 
hydrogels is polyethylene glycol (PEG) as its hydroxyl groups can be easily modified by functional 
groups or attached to other molecules or bioactive agents [33,41]. The embedding of hepatocytes into 
PEG hydrogels supported consistent urea synthesis and CYP3A4 activity in comparison to the 2D 
culture, while the combination with poly(lactic-co-glycolic) acid (PLGA) nanoparticles further improved 
hepatocyte function [33]. The combination of PEG hydrogels with abundant biomaterial from the liver or 
peptides that are required for the cell-ECM interaction, such as heparin or the Arg-Gly-Asp (RGD), 
resulted in significantly higher levels of albumin and urea synthesis in comparison to cells cultivated in 
the hydrogel alone [42,43]. One commercially available peptide hydrogel with self-assembling 
properties is PuraMatrix™ (3D Matrix Inc, Waltham, MA, USA). So far, the main disadvantages of 
these hydrogels are the high costs for the adjustment to high-throughput analysis and the low number 
of available data on hepatocytes [44,45]. 
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Table 2. Overview of static 3D cultivation systems for hepatocytes. 
3D System Source Cell Type Observation Reference 
Hydrogels     
Natural Collagen Human hepatocytes Sensitivity to acetaminophen-induced intoxication [3] 
 Matrigel Human Hepatocytes Enhanced formation of bile canalicular networks [38] 
Synthetic PEG  Functional groups can be attached to macromolecules [41] 
 +PGLA Human hepatocytes Consistent urea synthesis and increased CYP3A4 activity [33] 
 +Heparin Rat hepatocytes Stable urea and albumin synthesis for more than 3 weeks [42] 
 +RGD Rat hepatocytes 
Spheroid formation, maintenance of urea and albumin production for more 
than 4 weeks 
[43] 
 PuraMatrix™ Rat hepatocytes Higher albumin and urea levels for up to 3 weeks [44] 
Scaffolds     
Natural Chitosan  Provision of adhesion for hepatocytes [46] 
 +Heparin/alginate  Increased albumin synthesis [47] 
 +GHA  Increased albumin secretion and urea synthesis [48] 
 Alginate Rat hepatocytes 
Cell-cell and cell-extracellular matrix (ECM) interactions, phase I and phase 
II activity stable for one week, high urea and albumin synthesis 
[49] 
Synthetic PVA Rat hepatocytes Urea synthesis maintained over 5 days [50] 
 PLA Rat hepatocytes 
Maintenance of albumin and urea synthesis as well as CYP1A and UGT-
activity 
[51] 
 PS Rat hepatocytes Higher activity of CYP1A2, CYP2B1, and CYP3A2 [52] 
  Human hepatocytes Higher activity of CYP2B6 and CYP3A4 [37] 
Scaffold-free     
 Spheroids Human hepatocytes Metabolism of lamotrigine and salbutamol [53] 
 Nanoculture plate HepG2 
Enhanced expression of albumin, CYPs and liver-enriched transcription 
factors (HNF4-α and C/EBPα) 
[54] 




In order to overcome the above-mentioned pitfalls of hydrogels, porous scaffolds have been 
developed in recent years. Besides the cell-ECM interaction, the defined pore size of the scaffolds, 
which is achieved during fabrication, enables the establishment of cell-cell contacts which are essential 
for the maintenance of hepatic function [55]. Naturally derived scaffolds are either based on a single 
macromolecular carrier, such as chitin, alginate, chitosan, and gelatin, or on mixtures of these 
macromolecules [46,49]. The cultivation of hepatocytes on alginate scaffolds has revealed higher urea 
and albumin levels for up to one week, while CYP activities and conjugating phase II reactions 
remained stable [49]. Similar results have been obtained for the duration of 15 days by using a 
chitosan-gelatin or a chitosan scaffold in combination with alginate or heparin [46,56]. The main 
advantage of these naturally derived scaffolds consists in their biocompatibility that is, at the same 
time, their major drawback, as it may cause batch-to-batch variability. 
Attractive alternatives are synthetically derived polymer scaffolds with a high biocompatibility,  
such as scaffolds based on poly lactic acid (PLA), poly glycolic acid (PGA), or poly lactic-co-glycolic 
acids (PGLA), which were initially developed for tissue engineering and hepatocyte transplantation 
due to their biodegradability [57], or scaffolds based on polyvinyl alcohol (PVA) and polystyrene. 
Depending on the manufacturing process, these polymer scaffolds shape membranes, sponges or foam 
disks, which are all suitable for perfusion. The cultivation of hepatocytes on PVA scaffolds has led to 
the preservation of hepatocyte parameters, such as urea and albumin synthesis, for up to 5 days [50], 
while on PLA-based scaffolds, the activity of CYP1A and glucoronysl transferase has been kept stable 
for up to 15 days [51]. A comparable surface to traditional 2D culture is offered by polystyrene  
(PS) scaffolds, which are commercially available under the name Alvetex® (Reinnervate Ltd., Durham, 
UK). These scaffolds led to a higher activity of CYP1A2, CAP2B1, and CYP3A2 in rat hepatocytes,  
while CYP2B6 and CYP3A4 maintained their enzymatic activity in human hepatocytes [37,52].  
Another commercially available system is the Mimetix® system from the Electrospinning Company 
Ltd (Didcot, UK), which is based on polymer poly-L-lactide (PLLA) fibers. HepB2 cells cultivated for 
up to 28 days on these scaffolds exhibited a higher CYP activity as well as an increased albumin 
synthesis and detoxification [58]). However, the collaboration between Electrospinning and Medicyte 
may soon deliver first results from hepatocytes cultivated on Mimetix® scaffolds [59]. 
2.3.3. Scaffold-Free Cultivation 
The scaffold-free 3D cultivation of hepatocytes achieved a higher compliance through 
simplification and commercialization by different companies. The most critical point is the spheroid 
size, as spheroids which are larger than 200–300 μm are at risk of having necrotic areas, as oxygen 
diffusion is the main limiting parameter The approach of Scivax Inc. (Woburn, MA, USA) enables 
spheroid formation on nanoculture plates without the requirement of any scaffold. Spheroids generated 
from HepG2 cells displayed a higher expression of albumin, CYPs, and the hepatocyte-enriched 
transcription factors HNF4-α and C/EBPα [54]. The technique of the InSphero AG (Schlieren, 
Switzerland) enables the creation of self-assembling micro-tissues via the hanging-drop culture [36]. 
Reconstruction of micro-livers was enabled by generating spheroids of hepatocytes co-cultured with 
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different types of non-parenchymal liver cells, like e.g., endothelial cells, Kupffer cells or macrophages. 
The generated micro-livers exerted hepatic functions, such as bile canaliculi formation and glycogen 
storage, while in long-term culture for up to 14 days, the micro-tissues showed an increased sensitivity 
towards repeated doses of diclofenac [36] and nanomaterials [60]. A further improvement of this 
method will be achieved by combining hepatocytes and non-parenchymal liver cells with defined cell 
numbers from the same donor. An important step in this direction was recently accomplished by a 
protocol enabling the isolation of parenchymal and non-parenchymal liver cells from the same donor [16]. 
In summary, it has become evident that the three-dimensional cultivation techniques are superior to 
the standard cultivation conditions in 2D, as hepatocyte function is maintained by the different  
hydrogels and scaffolds. However, a clear comparison between the different cultivation techniques is 
difficult, as the design of the individual studies is heterogeneous and direct comparisons with 
established cultivation techniques, such as other devices and/or collagen sandwich or 2D cultures, have 
been limited in these studies. 
3. 3D Microfluidic Cultivation Systems for Primary Hepatocytes 
In order to create a more physiological environment for hepatocytes and to combat poor oxygen and 
nutrient diffusion, different perfusion systems have been developed. The main objectives of these 
efforts is the development of a fully functional cell culture model mimicking the complex in vivo 
architecture of a liver lobule which is suitable for toxicological and pharmacological drug screening 
and research. One of the main issues during the development of these devices is the balance between 
flow and shear stress applied to hepatocytes, as they are extremely sensitive to oxygen concentrations 
with a high metabolic demand, while they are also vulnerable to shear stress exceeding 0.03 Pa [61]. The 
viability of hepatocyte cultures under high shear is lower than for cultures under 2D conditions [62,63]. 
First attempts resulted in large-scale bioreactors that depended on high cell numbers and therefore 
caused high costs, both aspects prevented their routine application in research and drug development, 
while more recent developments focus on the miniaturization and high-throughput applications  
(Table 3). We are aware that many more 3D flow culture systems for hepatocytes have been 
established, but we focus here on those with the highest potential for acceptance in drug screening 
processes from our point of view.  
In the multi-compartment hollow-fiber bioreactor, cells attach to the surface of fibers and 
reorganize themselves to generate a microenvironment close to the physiological in vivo situation, 
while three interwoven hollow fibers ensure the supply with oxygen and nutrients [64]. The original 
device, which required 800 mL medium and several hundred million cells, has recently been  
down-scaled to 0.5 mL medium and 20 million cells [65]. Hepatocytes have maintained enzymatic 
activity and gene expression of CYP1A2, CYP3A4/5, CYP2C9, CYP2D6, CYP2B6, transporters, and 
phase II enzymes for up to 3 weeks [23,66]. In order to protect the cells from shear stress in the 
bioreactor, Miranda and co-workers (2010) encapsulated hepatocytes into alginate beads, thereby 
maintaining hepatocyte functionality for up to one month and enabling continuous sampling without 
termination of the ongoing experiments. 
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Table 3. Overview of 3D flow culture systems for hepatocytes. 
3D System Cell Type Observation Reference Manufacturer 
Hollow fiber bioreactor 
Rat hepatocytes Human 
hepatocytes 
Increased albumin synthesis and diclofenac toxicity 
higher expression of CYP1A2, CYP3A4/5, CYP2C9, 
CYP2D6, CYP2B6, transporters, and phase II enzymes 
[64,66–68] Unisyn 
Alginate encapsulated hepatocytes in 
the bioreactor 
Rat hepatocytes 
Enhanced biotransformation, CYP inducibility, albumin 
and urea secretion 




Up-regulation of CYP1A1, 1A2, 2B6, 2C9, 3A4, UGT, 
MDR1, and MRP2 
[70] University of Pisa 
Quasi-Vivo® Human hepatocytes 
Enables investigation of cross-talk between different cell 
types 
[71] Kirkstall 
LiverChip Human hepatocytes 
Maintained mRNA-levels of  
Phase I/II-enzymes over 7 days, higher or similar  
CYP-activities after day 4 
[72,73] 
CN Bio  
Innovations Limited 
HepaChip® Human hepatocytes 
Up-regulation of CYP3A4, CYP2A1, and phase II 
enzymes 
[52] NMI Reutlingen 
3D-KITChip HepG2, rat hepatocytes Higher level of differentiation [40] KIT 
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Another system applying low shear stress during cultivation is the multichamber modular bioreactor 
(MCmB). As several silicone culture chambers can be connected to each other, the interaction between 
the different chambers is solely based on soluble molecules in the cultivation medium, enabling the 
imitation of exchange between different tissues. However, single chambers can also be used for the 
cultivation of cells seeded onto scaffolds or embedded in hydrogels. After two weeks of culture, 
detoxification genes in hepatocytes, such as CYP1A1, 1A2, 2B6, 2C9, 3A4, UGT, MDR1, and MRP2, 
reached expression levels close to or above those of freshly isolated hepatocytes. Just recently, this 
cultivation system has been commercialized as the Quasi-Vivo® system (Kirkstall Ltd, Rotherham, 
UK). Like in other silicon-based systems, one main obstacle is the high substrate adsorption which 
could lead to an incorrect data interpretation [68]. 
Without a doubt, the development of these bioreactors has been an important step towards the  
in vivo situation and has improved our knowledge and understanding of hepatocyte biology. 
Nevertheless, the main disadvantages are the still required high cell numbers, which is in contrast to 
the restricted availability of these cells [8,16], their limitation to a few laboratories and the required 
expensive equipment and experienced personnel. Each of these aspects restricts their acceptance in 
drug research and highlights the demand for simplified systems, which are robust, reproducible, 
economic, and can easily be adapted to high-throughput screenings for drug testing. 
In the LiverChip (Table 3) multi-well platform, developed by Zyoxel (Oxfordshire, UK), cells are 
seeded onto implemented scaffolds. This platform focuses on three key aspects of hepatic physiology; 
i.e., the dynamic flow, the organization of cells into structures to mimic the architecture of the 
sinusoids, and the combined cultivation of hepatocytes and non-parenchymal cells [72]. Primary 
hepatocytes cultivated under these conditions exhibited a strong in vitro-in vivo correlation, which 
indicates a good predictability for hepatic clearance [21], while these cells also showed an in vivo like 
testosterone metabolism [72]. 
Another approach, developed by the Karlsruhe Institute of Technology (KIT), is based on a 
polycarbonate or polymethylacrylate polymer chip [40]. Cells seeded onto the polymer chip  
have generated three-dimensional structures in the porous microcavities (Figure 1a) of typically  
300 µm in each direction, and the human carcinoma cell line HepG2 exhibited a higher expression of  
uridine-diphosphate-glucosyl-transferase and glutathione-S-transferase. Short-term cultivation of 
primary human hepatocytes under perfusion conditions (400 μL/h) for 24 h in these polymer chips 
revealed cell clustering (Figure 1b), while the cells exhibited a good viability (Figure 1c). Furthermore, 
primary human hepatocytes seeded into the r-3D-KITChip demonstrated a higher rate of glucose 
production (Figure 2a), a higher detoxification rate (Figure 2b), and a higher multidrug resistant 
protein 1 (MRP1) (Figure 2c) activity than cells cultivated under 2D monolayer conditions. These 
differences between the two cultivation systems were even more pronounced when primary human 
hepatocytes were stressed by 100 μM and 1000 μM acetaminophen (Figure 3). Hepatocytes cultivated 
in the r-3D-KITChip under a continuous flow displayed a significantly higher sensitivity towards 
acetaminophen-induced intoxication, confirming our previously published data on static 3D culture [3]. 
A recently developed semi-automated system, the so-called HepaChip® is a microfluidic system, 
which mimics hepatic sinusoids. On the area of a microscopic slide, each one of the eight micro-chambers 
contains three cell assembly ridges with the length and width of a human liver sinusoid [74]. Two 
electrodes in each chamber enable accurate cell positioning. In a short-term experiment of about 3 h, 
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hepatocytes cultivated in the HepaChip®, had a significant higher activity of CYP3A4, CYP1A2, and 
phase II enzymes than hepatocytes co-cultivated in 96-well plates in the presence of endothelial cells [74]. 
The small volume and the low amount of required cells are an advantage of the HepaChip®, while its 
widespread application might be limited by the required sophisticated equipment. 
The ibidi® µ-Slide VI 0.4 is a commercially available microfluidic platform with six channels which 
can be perfused in parallel [34]. Its main advantages are the possibility to combine it with different 
hydrogels and its suitability for live cell imaging. While we have already demonstrated that the 
functionality of primary human hepatocytes is maintained for up to 28 days under static conditions [34], we 
wanted to compare the viability of human hepatocytes under static conditions compared with the 
cultivation in the ibidi® µ-Slide VI 0.4 under flow conditions for the duration of one week. 
Interestingly, the comparison between the 3D static cultivation and the 3D flow cultivation in the  
µ-Slide VI 0.4 indicated an improved viability and an increased glucose production in the primary 
hepatocytes exposed to flow for 7 days (Figure 4). These promising first results point out that the 
exposure to flow under 3D cultivation conditions might improve and maintain hepatocyte function for 
up to 7 days. In the future, we will investigate these findings further under long-term cultivation 
conditions. The validation of the µ-Slide VI 0.4 for the 3D flow cultivation of human hepatocytes 
would result in a device with simplified equipment and handling, two main aspects which currently are 
hindering numerous 3D cultivation systems from high-throughput and broad application in different 
laboratories and drug testing. 
 
Figure 1. The viability of primary human hepatocytes seeded into the r-3D-KITChip.  
(a) Image of the cavities of the r-3D-KITChip; (b) Bright-field images of primary human 
hepatocytes seeded into the r-3D-KITChip and in 2D (upper part). In the lower part, dead 
cells have been differentiated from the living cells by staining the living cells with  
2 μM Calcein AM, while dead cells were stained with 4 μM ethidium homodimer. Pictures 
were taken with an Evosfl microscope from Peqlab Biosystems (Erlangen, Germany). The 
scale bar corresponds to 400 μm; (c) In order to evaluate cell survival of primary human 
hepatocytes, resazurin conversion into resorufin was measured and normalized to mg 
protein in comparison to 2D cultivation conditions. The graphic was drawn with the 
GraphPad Prism software (GraphPad Software, version 5.01, San Diego, CA, USA). 




Figure 2. Functional parameters of primary human hepatocytes in the r-3D-KITChip and 
under 2D monolayer conditions on collagen coated cell culture plates. After attachment 
over night and perfusion for 24 h in the r-3D-KITChip, the culture medium was replaced by 
a buffer containing 1 mM magnesium chloride and 1 mM sodium pyruvate. The perfusion 
was continued for 24 h and cell culture supernatants were used for measuring basal glucose 
levels. (a) Basal glucose production; (b) Urea synthesis; (c) multidrug resistant protein 1 
(MRP1) activity. Cells were cultivated either in the r-3D-KITChip or under 2D conditions 
in the presence of 5-carboxyfluorescein diacetate (5-CFDA). After uptake, 5-CFDA was 
metabolized into the fluorophore 5-CF, which was detected in the cell culture supernatants 
after the indicated time points. The graphs were drawn with the GraphPad Prism software 
(GraphPad Software, version 5.01). The values are depicted as mean and standard 
deviation of three donors. 
 
 
Figure 3. Cultivation in the r-3D-KITChip sensitizes primary human hepatocytes to 
acetaminophen-induced intoxication. The cells were cultivated in the presence of 
acetaminophen (100 μM and 1000 μM) for 24 h. Their viability was determined by the 
conversion of resazurin into resorufin and is depicted as % of untreated cells. The graph 
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was drawn with GraphPad Prism software (GraphPad Software, version 5.01). Values are 
depicted as mean and standard deviation of three donors/experiments. 
 
 
Figure 4. Primary human hepatocytes entrapped in rat-tail collagen combined with 
continuous flow in the µ-Slide VI 0.4 show a higher viability and glucose production.  
Cells were either seeded in 2D or 3D in 96-well plates (2.5 × 104 cells/well) or entrapped 
in collagen in the µ-Slide VI 0.4 (1.5 × 105 cells/µ-Slide VI 0.4) and cultivated for 1 day or  
7 days. To evaluate cell viability, the cells were stained either with 2 μM Calcein AM to 
visualize living cells or with 4 μM ethidium homodimer to visualize dead cells, while the 
turnover of resazurin to resorufin was measured in parallel. The glucose production was 
measured from cell culture supernatants. (a) Live/dead staining of primary human 
hepatocytes on day one and day seven. Pictures were taken with an Evosfl microscope from 
Peqlab Biosystems (Erlangen, Germany); (b) Comparison of resazurin turnover and 
glucose production. Cell viability is depicted as % of viable cells compared to day one. The 
graphs were drawn with the GraphPad Prism software (GraphPad Software, version 5.01). 
The values are depicted as mean and standard deviation of three donors/experiments. 
So far, many promising systems for the 3D cultivation of primary human hepatocytes have been 
developed. As most of these systems have not been tested under uniform conditions, further inter- and 
intra-laboratory testing on a larger scale is urgently required. Three recent announcements of newly 
funded projects will hopefully deliver more data in this direction in the near future. Electrospinning 
and Medicyte have started a co-operation with the objective to characterize the biotransformation of 
Medicyte’s upcytes® on Alvetex® scaffolds [59]. In a collaboration between InSphero and the group of 
Ingelman-Sundberg at the Karolinska Insitute (Stockholm, Sweden) the predicitivity of InSphero’s 
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human 3D liver model (3D InSight TM Human Liver Microtissue) will be investigated [75]. 
Furthermore Promethera will use the CellASIC® microfluidic cell culture platform from EMD 
Millipore to improve preclinical liver toxicity testing methods [76].  
The detailed comparison of the generated data in these three projects with existing cultivation 
systems, like e.g., the 2D conditions, will deliver more reliable data regarding the improvement of the 
3D cultivation platforms. 
4. Conclusions 
One of the main objectives concerning the improvement of hepatocyte culture is the maintenance of 
hepatocyte function. As monolayer cultivation results in a rapid loss of drug-metabolizing enzyme 
activities, an increasing number of attempts has focused on the cultivation of hepatocytes in different 
matrices, either naturally derived or based on synthetic scaffolds, in order to mimic a 3D environment. 
Recently, numerous attempts have been made to get closer to the in vivo situation, as the 3D culture 
has been combined with perfusion. The main limitation of the first devices was the required number of 
cells, which is in contrast to the limited availability of primary human hepatocytes. Miniaturization of 
existing bioreactors through the development of microfluidic devices led to a reduction of the required 
cell numbers. In order to validate the maintenance of hepatic function in these systems over long-term 
periods additional data and the direct comparison to the monolayer cultures are required. 
Another main obstacle for some of these devices could be the requirement of expensive equipment 
and their complex handling. For a high acceptance in the drug testing industry and research a 
simplification of existing devices and their compatibility with high-throughput combined in a  
user-friendly platform must be achieved. 
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